Seagen to Host Virtual R&D Day on November 16, 2020
November 02 2020 - 8:00AM
Business Wire
Seagen Inc. (Nasdaq: SGEN) announced today that it will host a
virtual R&D day for investors and analysts on Monday, November
16, 2020 beginning at 10:00 a.m. Eastern Time. The program will
include a presentation by members of Seagen leadership on the broad
clinical development of the Company’s marketed products, ADCETRIS®
(brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv) and
TUKYSA® (tucatinib), and its deep pipeline of innovative therapies
for cancer.
Access to the event will be available at the Company’s website
www.seagen.com in the Investors section. A replay will be archived
on the Company’s website following the live presentation.
About Seagen
Seagen Inc. is a global biotechnology company that discovers,
develops and commercializes transformative cancer medicines to make
a meaningful difference in people’s lives. Seagen is headquartered
in the Seattle, Washington area, and has locations in California,
Canada, Switzerland and the European Union. For more information on
our marketed products and robust pipeline, visit www.seagen.com and
follow @SeagenGlobal on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201102005326/en/
Investors: Peggy Pinkston (425) 527-4160 ppinkston@seagen.com
Media: Monique Greer (425) 527-4641 mgreer@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024